Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Operating Leases (2019 - 2025)

Dexcom (DXCM) has disclosed Operating Leases for 7 consecutive years, with $73.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 12.92% to $73.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73.4 million, a 12.92% increase, with the full-year FY2025 number at $73.4 million, up 12.92% from a year prior.
  • Operating Leases was $73.4 million for Q4 2025 at Dexcom, up from $50.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $111.3 million in Q1 2021 to a low of $50.6 million in Q3 2025.
  • A 5-year average of $82.2 million and a median of $82.8 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: surged 45.32% in 2021, then fell 28.83% in 2025.
  • Dexcom's Operating Leases stood at $98.6 million in 2021, then dropped by 4.06% to $94.6 million in 2022, then dropped by 15.33% to $80.1 million in 2023, then dropped by 18.85% to $65.0 million in 2024, then increased by 12.92% to $73.4 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Operating Leases are $73.4 million (Q4 2025), $50.6 million (Q3 2025), and $54.7 million (Q2 2025).